Compare SHIM & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | CNTX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.5M | 116.7M |
| IPO Year | 2023 | 2021 |
| Metric | SHIM | CNTX |
|---|---|---|
| Price | $3.14 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 37.3K | ★ 680.8K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,984,000.00 | N/A |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $13.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $0.49 |
| 52 Week High | $3.50 | $1.55 |
| Indicator | SHIM | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 57.08 |
| Support Level | $2.60 | $1.08 |
| Resistance Level | $2.98 | $1.34 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 78.41 | 64.18 |
Shimmick Corp is a provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.